Very possible - we do know from midterm results of

Very possible - we do know from midterm results of the first 195 patients there were aprox 45 deaths so nearly the same amount in the second half. All signs pointing towards leronlimab kept the overall mortality near 22% first half of trial and 2nd half trial. I believe this favors the results being really good. If we saw that deaths were significantly lower in the the 2nd half of patients one coulda made the argument well SOC made great improvements and woulda been tough to show benefit however we know that’s not the case and quite the opposite as no drug has shown to be able to sign if ACM reduce mortality in covid severe-critical.

If we use what I think conservative 31% mortality rate on 394 patients = 122. will use estimate of 90 deaths total in trial. 31% vs overall of 22% the leronlimab % would have to be close to 18%-19%. 42% mortality reduction in leronlimab arm could be slightly more or less but that’s my best guesstimate.